Primary spinal cord high-grade gliomas, including those histologically identified as glioblastoma (GBM), are a rare entity in the pediatric population but should be considered in the differential diagnosis of intramedullary lesions. Pediatric spinal cord high-grade gliomas have an aggressive course with poor prognosis. The aim of this case report is to present a 15-year-old female adolescent with histopathologically confirmed spinal cord GBM with H3F3A K27 M mutation consistent with a diffuse midline glioma (DMG), H3 K27-altered, CNS WHO grade 4 with leptomeningeal seeding on initial presentation. As imaging features of H3 K27-altered DMGs are non-specific and may mimic more frequently encountered neoplastic diseases as well as demyelinating disorders, severe neurological deficits at presentation with short duration, rapid progression, and early leptomeningeal seeding should however raise the suspicion for a pediatric-type diffuse high-grade glioma like DMG, H3 K27-altered.
OstromQTCioffiGGittlemanH, et al.CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro Oncol2019; 21: v1–v100. DOI: 10.1093/neuonc/noz150.
3.
OstromQTPatilNCioffiG, et al.CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017. Neuro Oncol2020; 22: iv1–iv96. DOI: 10.1093/neuonc/noaa200.
4.
Sanchez-HerreraFCastro-SierraEGordillo-DominguezLF, et al.Glioblastoma multiforme in children: experience at Hospital Infantil de Mexico Federico Gomez. Childs Nerv Syst2009; 25: 551–557. DOI: 10.1007/s00381-008-0780-8.
5.
SongDXuDGaoQ, et al.Intracranial metastases originating from pediatric primary spinal cord glioblastoma multiforme: a case report and literature review. Front Oncol2020; 10: 99. DOI: 10.3389/fonc.2020.00099.
6.
LouisDNPerryAWesselingP, et al.The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol2021; 23: 1231–1251. DOI: 10.1093/neuonc/noab106.
7.
AboianMSSolomonDAFeltonE, et al.Imaging characteristics of pediatric diffuse midline gliomas with histone H3 K27M mutation. AJNR Am J Neuroradiol2017; 38: 795–800. DOI: 10.3174/ajnr.A5076.
8.
BananRAkbarianASamiiM, et al.Diffuse midline gliomas, H3 K27M-mutant are associated with less peritumoral edema and contrast enhancement in comparison to glioblastomas, H3 K27M-wildtype of midline structures. PLoS One2021; 16: e0249647. DOI: 10.1371/journal.pone.0249647.
9.
ChengLWangLYaoQ, et al.Clinicoradiological characteristics of primary spinal cord H3 K27M-mutant diffuse midline glioma. J Neurosurg Spine2021; 1–12. DOI: 10.3171/2021.4.SPINE2140.
10.
ChengRLiDPZhangN, et al.Spinal cord diffuse midline glioma with histone H3 K27M mutation in a pediatric patient. Front Surg2021; 8: 616334. DOI: 10.3389/fsurg.2021.616334.
11.
KrausTFJMacheggerLPoppeJ, et al.Diffuse midline glioma of the cervical spinal cord with H3 K27M genotype phenotypically mimicking anaplastic ganglioglioma: a case report and review of the literature. Brain Tumor Pathol2020; 37: 89–94. DOI: 10.1007/s10014-020-00365-z.
12.
KumarARashidSSinghS, et al.Spinal cord diffuse midline glioma in a 4-Year-Old Boy. Child Neurol Open2019; 6: 2329048X1984245. DOI: 10.1177/2329048X19842451.
13.
NavarroREGolubDHillT, et al.Pediatric midline H3K27M-mutant tumor with disseminated leptomeningeal disease and glioneuronal features: case report and literature review. Childs Nerv Syst2021; 37: 2347–2356. DOI: 10.1007/s00381-020-04892-0.
14.
UpparAKonarSKNandeeshBN, et al.H3K27M-positive primary spinal glioblastoma presenting with hemorrhage-a rare clinical entity. World Neurosurg2019; 126: 223–227. DOI: 10.1016/j.wneu.2019.03.025.
15.
WangLLiZZhangM, et al.H3 K27M-mutant diffuse midline gliomas in different anatomical locations. Hum Pathol2018; 78: 89–96. DOI: 10.1016/j.humpath.2018.04.015.
16.
YaoJWangLGeH, et al.Diffuse midline glioma with H3 K27M mutation of the spinal cord: a series of 33 cases. Neuropathology2021; 41: 183–190. DOI: 10.1111/neup.12714.
17.
CohenKJPollackIFZhouT, et al.Temozolomide in the treatment of high-grade gliomas in children: a report from the Children’s Oncology Group. Neuro Oncol2011; 13: 317–323. DOI: 10.1093/neuonc/noq191.
18.
LouisDNOhgakiHWiestlerOD, et al.The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol2007; 114: 97–109. DOI: 10.1007/s00401-007-0243-4.
19.
LouisDNPerryAReifenbergerG, et al.The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol2016; 131: 803–820. DOI: 10.1007/s00401-016-1545-1.
20.
LouisDNOhgakiHWiestlerOD, et al.WHO Classification of Tumours of the Central Nervous System. 4th ed.Lyon: IARC Press; International Agency for Research on Cancer, 2016.
21.
FerrantePMoraJASalazarL, et al.MR imaging findings in primary spinal cord glioblastoma. Radiol Case Rep2021; 16: 72–77. DOI: 10.1016/j.radcr.2020.10.043.
22.
KoellerKKRosenblumRSMorrisonAL. Neoplasms of the spinal cord and filum terminale: radiologic-pathologic correlation. Radiographics2000; 20: 1721–1749. DOI: 10.1148/radiographics.20.6.g00nv151721.
23.
KonarSKBirSCMaitiTK, et al.A systematic review of overall survival in pediatric primary glioblastoma multiforme of the spinal cord. J Neurosurg Pediatr2017; 19: 239–248. DOI: 10.3171/2016.8.PEDS1631.
24.
WolffBNgARothD, et al.Pediatric high grade glioma of the spinal cord: results of the HIT-GBM database. J Neurooncol2012; 107: 139–146. DOI: 10.1007/s11060-011-0718-y.
25.
OnoniwuCMehtaVBettegowdaC, et al.Pediatric spinal glioblastoma multiforme: current treatment strategies and possible predictors of survival. Childs Nerv Syst2012; 28: 715–720. DOI: 10.1007/s00381-012-1705-0.
26.
BirzuCTranSBielleF, et al.Leptomeningeal spread in glioblastoma: diagnostic and therapeutic challenges. Oncologist2020; 25: e1763–e1776. DOI: 10.1634/theoncologist.2020-0258.
27.
SturmDWittHHovestadtV, et al.Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell2012; 22: 425–437. DOI: 10.1016/j.ccr.2012.08.024.
28.
YanHParsonsDWJinG, et al.IDH1 and IDH2 mutations in gliomas. N Engl J Med2009; 360: 765–773. DOI: 10.1056/NEJMoa0808710.
29.
CohenARWisoffJHAllenJC, et al.Malignant astrocytomas of the spinal cord. J Neurosurg1989; 70: 50–54. DOI: 10.3171/jns.1989.70.1.0050.
30.
Kleinschmidt-DeMastersBKMulcahy LevyJM. H3 K27M-mutant gliomas in adults vs. children share similar histological features and adverse prognosis. Clin Neuropathol2018; 37: 53–63. DOI: 10.5414/NP301085.
31.
OndaKTanakaRTakahashiH, et al.Cerebral glioblastoma with cerebrospinal fluid dissemination: a clinicopathological study of 14 cases examined by complete autopsy. Neurosurgery1989; 25: 533–540.
32.
MandelJJYust-KatzSCachiaD, et al.Leptomeningeal dissemination in glioblastoma; an inspection of risk factors, treatment, and outcomes at a single institution. J Neurooncol2014; 120: 597–605. DOI: 10.1007/s11060-014-1592-1.
33.
NohJHLeeMHKimWS, et al.Optimal treatment of leptomeningeal spread in glioblastoma: analysis of risk factors and outcome. Acta Neurochir2015; 157: 569–576. DOI: 10.1007/s00701-015-2344-5.
34.
AndersenBMMirandaCHatzoglouV, et al.Leptomeningeal metastases in glioma: the memorial Sloan Kettering Cancer Center experience. Neurology2019; 92: e2483–e2491. DOI: 10.1212/WNL.0000000000007529.
35.
CivitelloLAPackerRJRorkeLB, et al.Leptomeningeal dissemination of low-grade gliomas in childhood. Neurology1988; 38: 562–566. DOI: 10.1212/wnl.38.4.562.
36.
HukinJSiffertJCohenH, et al.Leptomeningeal dissemination at diagnosis of pediatric low-grade neuroepithelial tumors. Neuro Oncol2003; 5: 188–196. DOI: 10.1215/S1152851702000297.
37.
DonsonAMAddo-YoboSOHandlerMH, et al.MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer2007; 48: 403–407. DOI: 10.1002/pbc.20803.
